Aktis Oncology, Inc.
Aktis Oncology, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing targeted radiopharmaceutical therapies for solid tumors. Its platform centers on miniprotein radioconjugates designed to deliver alpha-emitting radioisotopes to specific cancer targets, with programs aimed at multiple tumor types.
Business
Share of revenueClinical-stage alpha-emitting radioconjugate programs designed for specific tumor targets.
Discovery and IND-enabling programs for additional targeted oncology candidates.
Miniprotein radioconjugate platform used to identify and advance new tumor targets.
Revenue recognized from research collaboration agreements with strategic partners.
Customers
Aktis Oncology’s direct customers are primarily collaboration partners and, eventually, oncology physicians and cancer centers that would use approved radiopharmaceuticals. In the current stage, value is created through licensing, research collaboration, and development partnerships rather than commercial product sales. If approved, the end users would be patients with solid tumors expressing the relevant targets, treated through specialized oncology and nuclear medicine channels.
Biopharma partners that fund or co-develop radiopharmaceutical programs and share development risk.
Specialty cancer centers that would administer approved radiopharmaceutical therapies.
Patients whose tumors express Nectin-4, B7-H3, or other selected targets.
Specialized sites that would handle isotope preparation, handling, and administration.
Strategy
The company is focused on broadening targeted radiopharmaceuticals beyond the best-known tumor targets by advancing next-generation candidates against new antigens. It is also building supply, manufacturing, and development capabilities so that clinical demand and eventual commercial demand can be supported across multiple indications. Collaboration, licensing, and capital raising remain important to fund development until product sales are possible.
Clinical progress is required to validate the platform and create future product value.
Reliable access to 225Ac and production capacity is essential for trials and eventual commercialization.
Development-stage oncology programs require substantial capital before product revenue exists.
Geography
Aktis Oncology is headquartered in the United States and conducts its research, development, and corporate activities from there. Its business model is global in potential reach because radiopharmaceutical candidates may be developed for broad oncology use, but the disclosed operating footprint is centered in the U.S. The company also depends on external vendors and supply sources that may be located outside the U.S. for isotopes, manufacturing, and research services.
Risks
Aktis Oncology faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and the possibility that candidates never reach approval. Its radiopharmaceutical model also depends on specialized isotope supply, manufacturing execution, and intellectual property protection, all of which can constrain development or commercialization. Because the company has no approved products, it remains exposed to financing risk and to competition from other oncology and radiopharmaceutical platforms.
The company has no approved products and depends on successful trial outcomes to create value.
Exposure: Lead and pipeline candidates
The business requires sufficient 225Ac and related isotopes to run trials and support future supply.
Exposure: Clinical and commercial production
Radiopharmaceuticals require specialized handling, production, and logistics capabilities.
Development-stage operations require ongoing capital before product sales begin.
Other companies are developing targeted radiopharmaceuticals and oncology therapies for similar markets.
Exposure: Target selection and platform differentiation
Accounting
Judgemental itemsRevenue from the Eli Lilly collaboration is recognized over time, so reported revenue depends on incurred costs and progress.
Impact: Can create uneven quarterly revenue recognition
Clinical, preclinical, and manufacturing costs are expensed as incurred and can vary sharply by program stage.
Impact: Affects operating loss comparability across periods
License agreements may require future payments if development or commercial milestones are achieved.
Impact: Potential future cash outflows and expense recognition
Employee-related costs include equity awards, which affect operating expense and dilution analysis.
Impact: Impacts reported R&D and G&A expense
The company has accumulated losses and tax attributes that may not be realized.
Impact: Limits near-term tax benefit recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Egetis Therapeutics
EGTX · Health Care
Egetis Therapeutics is an innovative pharmaceutical company specializing in the development and commercialization of treatments for serious diseases with…
Nektar Therapeutics
NKTR · Pharmaceutical Preparations
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer.
Citius Oncology, Inc
CTOR · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Acrivon Therapeutics, Inc.
ACRV · Pharmaceutical Preparations
Last updated: 11/08/2026